ArticleJCO precision oncology2020
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring
Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Intracranial Activity of Selpercatinib in Chinese Patients With AdvancedJCO precision oncology · 2023Trial
- Intracranial Efficacy of Selpercatinib inClinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Selpercatinib as First-Line Therapy in a 9-Month-Old Infant With MetastaticJCO precision oncology · 2026Article
- Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Case Report: CD34-Negative, S100-Positive Spindle Cell Tumor With aCase reports in pathology · 2025Article
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis.Science translational medicine · 2024Review
- Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.Biochemical pharmacology · 2023Review
- Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.World journal of pediatrics : WJP · 2023Article
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.Molecular therapy oncolytics · 2023Article
- Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics · 2023Review
- Precious Gene: The Application of RET-Altered Inhibitors.Molecules (Basel, Switzerland) · 2022Review
- Review
- Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.Cancer research · 2022Article
- Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.Nature medicine · 2022Observational
- The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.Cancer discovery · 2022Article
- Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.Cancer research · 2022Article
- Precision oncology forFrontiers in oncology · 2022Review
- Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.